Study in people with HIV and mice identifies new mechanism — and drug target — for memory decline.
Northwestern University news release
A class of flu drugs may reduce cognitive decline and premature aging in people living with chronic viral infection, reports a new study led by Northwestern University that began with blood samples from people with HIV and extended into preclinical drug trials.
The findings point to a potential new therapy for cognitive problems in people with HIV, with broader implications for other aging-related diseases, such as dementia.
At least a quarter of people living with HIV develop problems with memory and thinking, even with effective antiretroviral treatment. Reasons for these cognitive symptoms have remained unclear. In this study, the Northwestern scientists identified a new biological culprit: the degradation of protective sugar molecules in our bodies, known as glycans, that normally help keep inflammation in check. When inflammation becomes chronic, it can accelerate biological aging by driving the immune system to overreact for too long.
The scientists identified the new sugar mechanism by analyzing blood samples from more than 100 individuals with HIV, both with and without cognitive impairment. Then, the research team conducted lab and mouse studies, where they found that flu drugs (a combination of Tamiflu and another experimental drug) preserved the sugar molecules and protected the brain.
Read the full news release here.
Source : Northwestern University
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.